For many patients with EGFR-mutated lung cancer, targeted therapies have transformed outcomes. Drugs designed to block EGFR signalling have become a cornerstone of treatment for the most common EGFR mutations – exon 19 deletions and the L858R mutation in exon 21.
However, not all EGFR mutations respond in the same way. EGFR exon 20 insertions represent a distinct and clinically important subgroup that behaves differently from other EGFR mutations and requires a different treatment approach.
Dr Dionysis Papadatos-Pastos, a consultant medical oncologist specialising in lung cancer in London, explains what EGFR exon 20 insertions are, why they present a particular clinical challenge, and what treatment options are now available.
Topics Covered
Topics Covered
Topics Covered
Topics CoveredWhat Is an EGFR Exon 20 Insertion?
The EGFR gene contains regions called exons, each encoding part of the EGFR protein. Mutations in different exons produce different effects on how the protein functions and how the tumour responds to treatment.
EGFR exon 20 insertions are a group of mutations in which extra genetic material is inserted into exon 20 of the EGFR gene. This insertion changes the shape of the EGFR protein in a way that keeps it permanently active, driving continuous tumour growth.
What makes exon 20 insertions clinically distinctive is that this structural change also makes the mutant protein much less accessible to the standard EGFR inhibitors that work well for exon 19 deletions and L858R mutations. As a result, conventional first- and second-generation EGFR targeted therapies have little activity against exon 20 insertions — and patients with this mutation historically had fewer targeted options available to them.
How Common Are EGFR Exon 20 Insertions?
EGFR exon 20 insertions account for approximately 1–3% of all non-small cell lung cancer (NSCLC) cases. While this may appear small, it represents a meaningful patient population given how common lung cancer is overall.
Within EGFR-mutated lung cancers specifically, exon 20 insertions make up around 5–12% of EGFR mutations — placing them third in frequency after exon 19 deletions and L858R.
Like other EGFR mutations, exon 20 insertions are found more commonly in:
- patients who have never smoked or who have a limited smoking history
- those with adenocarcinoma histology
- patients from East Asian backgrounds, though they occur across all ethnicities
Why Standard EGFR Inhibitors Do Not Work
Understanding why conventional EGFR inhibitors are ineffective against exon 20 insertions requires a brief explanation of how these drugs work.
Standard EGFR inhibitors — including first-generation drugs such as gefitinib and erlotinib, and third-generation osimertinib — bind to a specific site within the EGFR protein to block its signalling. For exon 19 deletions and L858R mutations, these drugs fit well and achieve strong inhibition.
In exon 20 insertions, the extra genetic material alters the shape of the binding site, making it harder for conventional inhibitors to bind effectively. The protein remains active despite the presence of the drug, and the tumour continues to grow.
This is why accurate molecular testing — specifically identifying the precise nature of the EGFR mutation — is so important. A patient identified as having an EGFR mutation but not further classified may receive a targeted therapy that is unlikely to be effective for their specific subtype.
How Is EGFR Exon 20 Insertion Diagnosed?
EGFR exon 20 insertions cannot be detected through imaging or standard pathology alone. Comprehensive molecular testing is essential and is now a standard part of the assessment for patients with advanced or metastatic NSCLC.
Testing is typically performed on tumour tissue obtained through biopsy. Liquid biopsy using circulating tumour DNA from a blood sample may also detect exon 20 insertions in selected situations, and can be useful when tissue is limited or when reassessment is needed during treatment.
Importantly, not all molecular testing platforms detect exon 20 insertions with equal sensitivity. Panels that include next-generation sequencing (NGS) are better suited to identifying the range of insertion variants that can occur. This is one reason why specialist input into the choice of testing platform can make a meaningful difference to diagnostic accuracy.
Treatment Options for EGFR Exon 20 Insertion Lung Cancer
Until relatively recently, patients with EGFR exon 20 insertions had limited targeted options and were often treated with chemotherapy and immunotherapy — standard approaches but ones not tailored to the specific biology of their tumour.
The development of therapies specifically designed to target the structural features of the exon 20 insertion has changed this picture considerably.
Agents that have shown clinical activity against EGFR exon 20 insertions include amivantamab, a bispecific antibody targeting both EGFR and MET. Other agents are in various stages of clinical development.
These therapies have demonstrated meaningful responses in patients with exon 20 insertion-positive NSCLC, both in those who have received prior treatment and, more recently, in earlier lines of therapy. The evidence base is continuing to evolve, and clinical trials in this area remain an important consideration for eligible patients.
Treatment decisions in EGFR exon 20 insertion lung cancer are best made within a specialist multidisciplinary team with experience in molecular lung cancer, where the available evidence can be applied to each patient’s individual situation.
The Role of Private Specialist Care
Because EGFR exon 20 insertions are relatively uncommon and require specialist knowledge of both molecular testing and available therapies, patients often benefit from expert input beyond what may be available through a standard oncology pathway.
Private specialist care offers rapid access to a consultant with experience in precision oncology, dedicated time to discuss the specific nature of the mutation and its implications, and the opportunity to explore all available treatment options — including clinical trials — in detail.
For patients who have received a diagnosis of EGFR exon 20 insertion lung cancer and want to ensure that the full range of treatment options has been considered, a private specialist consultation can provide both clinical clarity and meaningful reassurance.
Conclusion
EGFR exon 20 insertions are a distinct subgroup of EGFR-mutated lung cancer that do not respond to the standard EGFR inhibitors used for more common EGFR mutations. Accurate molecular diagnosis, specialist knowledge of the available therapies, and access to clinical trials are all important in ensuring that patients receive the most appropriate treatment.
As the evidence base for exon 20-specific therapies continues to develop, specialist input — from a thoracic oncology consultant with experience in precision medicine — is particularly valuable for patients with this mutation.
If you have been diagnosed with EGFR exon 20 insertion lung cancer or would like a specialist review of your molecular test results and treatment options, Dr Papadatos-Pastos sees patients privately at several London clinics and is available for both in-person and virtual consultations.
Support and Follow-Up Care
Dr Papadatos-Pastos and his team provide ongoing support beyond medical treatment.
Patients receive clear communication, psychological care and access to nutrition, physiotherapy and symptom-management services.
Regular follow-up ensures early detection of recurrence and long-term wellbeing.
Book a Consultation
If you or someone close to you has been diagnosed with lung cancer, early consultation with a specialist can make a real difference. Appointments are available at several London clinics.
Faq
Answers to Common Questions
Answers to Common Questions About EGFR Exon 20 Insertion Lung Cancer
An EGFR exon 20 insertion is a type of genetic mutation in which extra material is inserted into exon 20 of the EGFR gene. This changes the shape of the EGFR protein and keeps it permanently active, driving tumour growth. Unlike more common EGFR mutations, exon 20 insertions do not respond well to standard EGFR targeted therapies.
The most common EGFR mutations — exon 19 deletions and the L858R mutation in exon 21 — respond well to standard EGFR inhibitors such as osimertinib. Exon 20 insertions create a different structural change in the EGFR protein that makes it much less sensitive to these drugs. Specific therapies designed to target the altered structure of exon 20 insertions are required.
EGFR exon 20 insertions account for approximately 1–3% of all NSCLC cases and around 5–12% of EGFR-mutated lung cancers. They are more commonly found in patients who have never smoked and those with adenocarcinoma histology.
Therapies specifically developed for EGFR exon 20 insertions include amivantamab and sunvozertinib. Sunvozertinib has recently received FDA approval specifically for this indication — it is important to note that this approval is currently from the FDA and not yet from other regulatory authorities such as the EMA or MHRA. Other agents are in development. Treatment decisions depend on individual circumstances, prior treatment history and clinical trial availability, and are best made with specialist guidance.
Standard EGFR inhibitors are designed to bind to a specific site on the EGFR protein that is accessible in common EGFR mutations. The structural change caused by an exon 20 insertion makes this site less accessible, meaning the drug cannot bind effectively and the tumour continues to grow despite treatment.
Clinical trials are an important consideration for patients with EGFR exon 20 insertions, particularly as several new agents are in active development. A specialist consultation can help identify relevant trials and assess eligibility based on individual circumstances.
Yes. Knowing that a tumour carries an EGFR mutation is important, but understanding the precise subtype — including whether it is an exon 20 insertion — is equally critical. Different EGFR mutations require different treatments, and not all testing platforms identify exon 20 insertions with equal accuracy. Next-generation sequencing panels are generally recommended for comprehensive molecular profiling.
Yes. Given the complexity of this subgroup and the importance of accurate molecular diagnosis in guiding treatment, a second opinion from a specialist in molecular lung cancer is entirely reasonable and may be helpful in ensuring that all available options have been considered.
